Interview with Jonathan Zhu, General Manager, Celgene China
Celgene is a relative newcomer to China. What’s the story behind how the company entered the market, and how did you yourself come to manage the local operations? I officially…
Address: No. 222, Huangpu District, Shanghai Yan’an East Road
, Bund Center, 1102 – Room 1104
Zip: 200002 ,China
Tel: +86 216 133 9333
The new base is committed to providing innovative medicines that can really change the life for patients. Our mission is to build a global enterprise based biopharmaceutical, while focusing on the exploration, development, and commercialization of pharmaceutical products for the treatment of cancer and other serious diseases such as immune and inflammatory.
Major medical centers about 300 a number of new base compounds of clinical trials. Compounds of these studies are for blood and solid tumor cancer patients suffering from an incurable research, including multiple myeloma, bone marrow hyperplasia anomaly syndrome, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL ), myelofibrosis, small cell lung cancer and prostate cancer.
As committed to the clinical achievements, we are equally committed to providing patient support, which is the guiding principle of the new base. We believe that all patients should be given the opportunity to benefit from our research. New base by the industry-leading program patients were placed in the first, to provide information, support, and our innovative therapies.
Revlimid
Celgene is a relative newcomer to China. What’s the story behind how the company entered the market, and how did you yourself come to manage the local operations? I officially…
2024 was another groundbreaking year for Chinese medicine approvals. Writing in the March 2025 edition of DIA’s Global Forum magazine, Juan Valencia S. and Angel Shao of PharmCube explain how…
Illumina has been swept into the trade conflict between the US and China. After the Trump administration declared a 10 percent tariff on Chinese goods in February, Beijing retaliated by…
A roundup of some of the biggest stories coming out of China’s pharma industry, including the news that AstraZeneca may be seeing the other side of country’s probes; the counter-sanction…
China’s position as one of the leading global sources and recipients of biopharmaceutical innovation is inarguable. However, in the new Year of the Snake, geopolitical and economic uncertainties are swirling,…
Over the course of its 350-year history, Merck KGaA has expanded from its base in Darmstadt, Germany to establish a strong presence in various markets across the globe. Last year,…
A summary of some of the latest news from China’s pharma industry, including AbbVie’s blood cancer licensing option with Simcere; Lonza’s China manufacturing expansion; Merck’s obesity deal with Hansoh Pharma;…
Throughout the year PharmaBoardroom has talked to pharma and biotech executives and life sciences opinion leaders across the globe, gathering vital insights into local markets, learning about promising new therapies,…
Since raising USD 289 million in its Spring 2020 Hong Kong IPO, InnoCare Pharma has had a remarkable rise. Led by a team of Big Pharma veterans and now also…
US-headquartered global genomic sequencing giant Illumina has endured a tough few years. However, now that various legal wrangles over its acquisition of cancer diagnostics developer GRAIL have been largely resolved…
Eye health, despite being essential for most of us in our daily lives, receives significantly less research funding than fields like cancer or diabetes. According to IQVIA, global spending on…
Diabetes is a growing health concern in China and – given the country’s population size – a major contributor to global diabetes levels. Indeed, a recent study in The Lancet…
There are over 7,000 different rare diseases globally, many of which affect only a handful of patients. However, given the scale of China’s population, rare diseases in the country take…
See our Cookie Privacy Policy Here
